Highlights Glenmark Life Sciences Limited Bombay S.E.

Equities

GLS

INE03Q201024

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-05-24 EDT			5-day change	1st Jan Change
841.4 ^INR	+2.26%		+1.02%	+28.05%

05-15	Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion	RE
04-25	Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion	05-15	RE
Glenmark Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	04-25	CI
Glenmark Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	04-25	CI
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited.	03-11	CI
Nirma Limited completed the acquisition of 0.000738% stake in Glenmark Life Sciences Limited.	02-28	CI
India's Glenmark Pharma posts loss for Q3 as remediation cost weighs	02-14	RE
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO	01-23	RE
Glenmark Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-23	CI
Paracetamol maker Granules India posts marginal rise in Q3 profit	01-23	RE
Glenmark Life Signs Master Supply Agreement with Japanese Drugmaker for Urinary Anti-Spasmodic API	01-19	MT
Glenmark Life Sciences Announces Another CDMO Deal	01-18	CI
India's Glenmark Pharma posts Q2 loss on exceptional legal costs	11-10	RE
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand	11-09	RE
India's Glenmark Life Sciences posts Q2 profit rise on API boost	23-10-20	RE
Glenmark Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-20	CI
Glenmark Life Sciences Limited Declares Interim Equity Dividend for the Financial Year 2023-24, Payable on or After October 23, 2023	23-10-09	CI
Indian paracetamol maker Valiant Laboratories lists at 16% premium	23-10-06	RE
Glenmark Life Sciences Limited Approves Interim Dividend for the Financial Year 2022-23	23-09-26	CI
Glenmark Pharmaceuticals to Divest Majority Stake in Glenmark Life Sciences for INR56.5 Billion	23-09-21	MT
Glenmark Pharmaceuticals Divests 75% in GLS to Nirma	23-09-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Glenmark Life Sciences Limited Bombay S.E.

Equities

GLS

INE03Q201024

Highlights

Filters